Introduction
Cystic fibrosis (CF) is an autosomal recessive disorder affecting 1 in 2500 live births in the UK [1] . This life-limiting condition (median predicted survival age˜47 years) [2] is the result of mutations in the CF transmembrane conductance regulator (CFTR) gene, characterized by impaired epithelial chloride transport, leading to an abnormally viscous mucous and poor lung clearance [3] . Obstructive pulmonary disease is the primary cause of morbidity and mortality (˜80%) within CF patients [4] . The ongoing cycle of infections caused by this thick, often stagnant, mucus in the lung necessitates chronic use of antibiotics. Patients eventually become colonized by multi-drug resistant (MDR) pathogens, particularly Pseudomonas aeruginosa, leading to chronic inflammation and reduced lung function [5] . Within the diseased CF lung, the viscoelasticity of mucus is altered by constituents such as lipids, proteins (e.g. IgM), DNA and mucins [6] .
Mucins are a large glycosylated protein component of mucus [7] . Although mucins represent < 1% (w/v) of respiratory secretions [8] [9] [10] , they are important gel-forming constituents in CF sputum [11] [12] [13] . They also play an important role in the innate immune system [14] both as a physical barrier against chemical, enzymatic and mechanical insult, and by providing a 'first line' of defense against pathogens [15] . Whilst important in defense, mucin barriers may impede drug delivery; with inhaled agents binding to the mucins and being rapidly removed by mucociliary clearance [16] . Methods to disrupt these muco-adhesive interactions, allowing crossing of the mucin-protective layer of the lung, would greatly improve drug delivery [17] . respiratory disease and these modifications cause changes in the viscoelastic properties of the mucus, as the addition of charged residues influences mucin aggregation [18] . CF mucins have been shown to possess increased levels of fucose, galactose, N-acetylglucosamine [19] , sialic acid and sulphate [12] . Furthermore, increases in glycosylation and branching in CF mucins have been shown to result in a higher tendency to 'gel' and obstruct transport in vivo [19] . It has also been demonstrated in CF that mucins may exhibit increased levels of expression of sialylated and sulphated-Lewis x determinants during inflammation and infection [8] . The sulphated Lewis x antigen is the main sulphated sugar in CF respiratory mucin [18] . Over sulphation in CF respiratory and salivary mucins has long been reported in the literature [20] [21] [22] [23] .
OligoG CF-5/20 is a low molecular weight oligosaccharide derived from the stem of brown seaweed, Laminaria hyperborea, and has recently completed Phase 2b clinical trials (NCT02157922; NCT02453789) as an inhalation therapy for CF patients. In previous in vitro studies, treatment with G-rich alginate oligomers was shown to alter the viscoelastic properties of mucin/alginate gels, mucin/DNA gels and CF sputum [24, 25] . OligoG CF-5/20 interacts with respiratory mucins, inducing alterations in mucin porosity and surface charge [25] . It has also been shown to potentiate antibiotics against a range of multidrug resistant bacteria (up to 512-fold) [26] . Further studies have confirmed its ability to alter the surface charge of P. aeruginosa leading to bacterial aggregation, a reduction in bacterial motility, and impaired biofilm formation [27, 28] . High MW alginate as secreted by virulent CF respiratory bacteria such as a mucoid P. aeruginosa, increase the elasticity and viscosity of mucus, whilst conversely, low Mw alginates have been shown to reduce the bulk elasticity and viscosity of mucus [29] . Interestingly, in vitro and in vivo studies have shown that low Mw alginate oligosaccharides are able to displace mucin-high MW alginate interactions, as might be expected to occur in the chronically infected lung.
This study used Fourier-transform infrared spectroscopy (FTIR) to examine direct physicochemical interactions of OligoG CF-5/20 with respiratory mucins in order to better understand how it is able to alter CF sputum viscosity. FTIR is a low-cost, high-throughput optical technology which requires only low volumes of test samples and has previously been employed to accurately characterize alterations in mucin expression, secretion and glycosylation (as well as in the Lewis x antigen structures) in respiratory disease [18, 30, 31] .
The aim of this study was to use mucin infrared (IR) profiles from our extensive spectral library (18) , to identify key IR markers to describe the structural changes and electrostatic interactions that occur within mucin glycan moieties and peptide backbone following OligoG CF-5/20 treatment of CF sputum.
Materials and methods

Patient samples
Induced sputum samples were collected from cystic fibrosis patients after obtaining informed written consent (CF Sputum Induction Trial [CF-SpIT] UKCRN: 14615). FTIR samples were collected from 13 patients (mean age 13.1 years; range 7-17 years; male to female ratio, 9:4 respectively). The mean FEV 1 (% predicted) was 73 (range 31 to 99%) with 69% of patients found to be infected with P. aeruginosa at the time of sampling (Table 1 ). Samples were collected by expectoration, after which they were stored by freezing at −80°C. Prior to subsequent use, sputum samples were defrosted overnight at 4°C.
Fourier-transform infrared spectroscopy of cystic fibrosis sputum
FTIR analysis was performed on CF patient sputum samples (n = 13 patients; Table 1 ) + 0.2% OligoG CF-5/20 or dH 2 O; 0.2% OligoG CF-5/ 20 reference spectra were also generated. CF sputum was incubated with 0.2% (w/v) OligoG CF-5/20 or dH 2 O (control) for 4 h at 37°C [25] . 3 μl of each sample was pipetted in triplicate onto a 96-well silicon plate (Bruker Optics Inc., Coventry, UK). Following drying at room temperature (1 h), high-throughput FTIR analysis was performed using a Bruker Vertex 70 in transmission mode with a KBr beamsplitter, DTGS detector and HTS-XT attachment. Spectra were acquired within the range of 4000-400cm −1 , at a resolution of 4 cm −1 with each spectrum being the averaged result of 32 scans. Each silicon plate was scanned in triplicate to ensure reproducibility of individual sample spectra.
All data processing, analysis and visualizations were performed using Bruker OPUS 7.5 software, and the R-statistical computing environment using in-built algorithms and code developed by our group. The whole infrared spectra were pre-processed prior to further analysis by baseline correction using the automatic 'rubberband' correction and vector normalization. Absorbance spectra were smoothed using a ninepoint Savitzky-Golay algorithm and second derivative spectra were calculated using a 9-point window. Based on our previously developed mucin glycosylation IR spectral library (18), we assessed the 'fingerprint' spectral region (absorbance values between wavenumbers 1800 and 900 cm −1 ). Statistically significant differences between peak positions or absorbance intensity at key wavenumbers in treated and control CF sputum samples were determined using the Mann-Whitney U Test. Multiple hypothesis testing was carried out on all statistical test results using the Bonferroni correction. Whilst many potential wavenumbers were investigated during this study, only those wavenumbers which showed promise for determining interaction between OligoG CF-5/20 were statistically examined. The following wavenumbers were identified and statistically examined due to presence of peaks in treated CF sputum spectra but not OligoG CF-5/20 spectra: 1652, 1637, 1240, 1116, 1080 and 1053 cm -1 . Therefore, the corrected α-level was 0.008.
Results and discussion
FTIR was used to generate absorbance spectra between wavenumbers 400 to 4000 cm −1 to establish biochemical changes following 0.2% (w/v) OligoG CF-5/20 incubation with CF sputum samples. Analysis was then performed on IR wavenumbers within the 900 to 1800 cm −1 'fingerprint' region to focus on key structural changes in mucin proteins and associated glycosylation. Fig. 1a shows the mean absorbance spectra for both untreated and treated CF sputum samples highlighting the wavenumber regions where IR absorbance patterns are altered post-treatment. The spectra were aligned with a representative OligoG CF-5/20 IR spectrum to easily identify regions of absorbance change that occurred due to OligoG CF-5/20 being present in the samples.
Raw absorbance IR spectra are a series of many peaks merged into broad peaks to determine the exact position of peak changes between untreated and OligoG CF-5/20 treated sputum spectra, whilst second derivative spectra are used to enhance the separation of any overlapping peaks. Second derivative spectra were calculated and aligned with that of OligoG CF-5/20 (Fig. 1b ). Comparison of OligoG CF-5/20treated and -untreated CF sputum second derivative spectra with a second derivative spectrum of 0.2% (w/v) OligoG CF-5/20 allowed determination of potential structural changes or interactions at key mucin peaks following OligoG CF-5/20 incubation of CF-patient sputum.
Mucin glycan changes in the presence of OligoG CF-5/20
IR peaks associated with mucin glycan moieties, including sialylated and sulphated Lewis x antigen, were initially assessed using known wavenumber absorbance data from our glycosylation IR spectral library [18] . Glycan associated structures, such as the CeO bonds in the pentose and hexose rings, absorb strongly between 900 and 1280 cm −1 , with numerous second derivative peaks being evident. Unfortunately, OligoG CF-5/20 also absorbs strongly within the same region as mucin glycans, with a number of key peaks identified at the same positions. As we were interested in determining sputum mucin-OligoG CF-5/20 interaction, and not just OligoG CF-5/20 presence in CF sputum, it was necessary to focus our analysis on wavenumbers that showed differences in absorbance, or peak presence which were not associated with OligoG peaks, as being indicators of OligoG CF-5/20 interaction. For example, Fig. 2a shows a second derivative peak at 1078 cm −1 , in the untreated sputum spectrum representing the major glycan-associated peak, shifted to 1070 cm −1 in the OligoG CF-5/20 treated sputum spectrum without a second derivative peak being evident in the OligoG CF-5/20 spectrum at the same wavenumbers. Fig. 2b shows that the distributions of major glycan-associated second derivative peak apex positions for all samples in the OligoG CF-5/20 treated sputum spectrum were significantly different from the untreated control samples ( Table 2 , P < 0. 008). We also observed that a peak at 1053 cm −1 was completely lost following sputum treatment with OligoG CF-5/20, although comparison with the OligoG CF-5/20 spectrum shows presence of a peak maxima in the OligoG CF-5/20 spectrum. This suggests that the second derivative peak loss at 1053 cm -1 may not be indicative of interaction between OligoG CF-5/20 and the sputum mucins, rather it could be indicative of OligoG CF-5/20 presence.
We next assessed the wavenumber region surrounding 1116 cm −1 which we had previously identified as probable absorbance from the sulphated-Lewis x antigen [18] . Fig. 3a shows that absorbance at 1116 cm −1 was lost following OligoG CF-5/20 treatment, suggesting an interaction of OligoG CF-5/20 with the sulphated-Lewis x antigen. Fig. 3b , summarized in Table 2 shows significant differences across all samples between treated and untreated for 1116 cm −1 . We also examined absorbance at, and peak positions around, 1240 cm −1 which is also indicative of absorbance by the sulphated-Lewis x antigen (Fig. 4a) .
A general but small shift in peak position towards lower wavenumbers in the OligoG CF-5/20 incubated sputum spectra, relative to untreated control sputum spectra (Fig. 4b) was observed. Additionally a small decrease in absorbance was observed at 1240 cm −1 in the incubated sputum spectra (Fig. 4c ). Although this could suggest a likely interaction between OligoG CF-5/20 and sulphated-Lewis x antigen, the decrease in absorbance at 1240 cm −1 in the incubated sputum spectra, and the peak shift were not found to have statistical significance. Within sputum, negatively-charged biopolymers such as mucin, DNA and alginates, assemble via physical entanglement of non-covalent bonds. As glycoproteins exhibit electrostatic, hydrophobic and hydrogen bonding interactions, mucin is able to readily adhere to other substances. Modification of the glycan chains of CF mucins has previously been hypothesized to increase bacterial binding and colonization in the CF lung. Alteration in mucin glycosylation has been demonstrated to potentiate P. aeruginosa binding to CF mucins when compared to non-CF mucins [32] . Glycan sulphation may increase with bacterial infection, possibly to protect the underlying glycoproteins from enzymatic degradation by bacteria [33] . Both inflammatory leukocytes and P. aeruginosa are thought to recognize sulphated ligands and lead to an inflammatory response and increased pathogenesis of P. aeruginosa respectively [21, 34] . Interestingly, increases in sulphation have been demonstrated in the absence of bacterial infection in CF, suggesting this may be a primary defect of the disease [35, 36] . However, other studies have reported a reduction in sulphation in CF patients when compared to healthy controls, leading some to dispute its significance in CF patients [37] . Nevertheless, changes in the sulphation peak in sputum observed in the current study suggest that OligoG CF-5/ 20 was able to bind to the sulphate moieties on the glycans, and in this way counteract the effects of pathogen recognition and binding [36] .
Reducing barriers to drug and gene delivery [38, 39] and modifying the properties of mucus may be beneficial in a range of clinical conditions such as CF [40] , and reproductive medicine [41] . Although mucin generally serves as a barrier to bacteria, several pathogens such as P. aeruginosa reside within mucus and possess mucin-specific adhesins [17] . Mucin interactions with P. aeruginosa have been shown to increase bacterial motility, which is partly directed by both quorum sensing (QS) and the physical properties of mucin [42] . In contrast, OligoG CF-5/20 has been shown to bind to the cell surface of P. aeruginosa, modifying its QS signaling pathways and reducing its motility [26, 28, 43] .
Mucin protein back bone changes in the presence of OligoG CF-5/20
To determine possible mucin peptide backbone alterations following incubation with OligoG CF-5/20, we examined the Amide I region between wavenumbers 1628 cm −1 and 1664 cm −1 (Fig. 5a ). This range was selected to include those peaks related to the random coil (1652 cm -1 ) and β-sheet (1637 cm -1 ) secondary structures that predominate in sputum mucins and to avoid amino sugar absorbance at 1626 cm −1 [30] . Through FTIR analysis of these wavenumbers, we have previously shown OligoG CF-5/20 is capable of binding to mucin [25] . Binding between OligoG CF-5/20 and CF mucins was also previously characterized using FTIR, demonstrating an interaction between OligoG CF-5/20 and the carbonyl group within the peptide link Table 2 Results of Paired Mann-Whitney signed rank tests for differences of means in absorbance intensity at the specified wavenumbers, and peak position around the selected wavenumbers.λ= < 0.008 mean of n = 3 replicates. of the mucin protein backbone found in the Amide I region [25] . It is possible that the experimental conditions, namely the drying of the sputum to form a thin film, could influence the protein secondary structure and therefore the peak positions. However, there are a number of publications which show that comparable protein secondary structure information is derived from circular dichroism and FTIR based experiments on protein solutions and on thin films [44] [45] [46] [47] . Therefore, it is reasonable to hypothesise that the experimentally required drying of the sputum was unlikely to cause alterations to the secondary structure of the mucins in our current study.
In the present study, we did not observe statistically significant (P > 0.008) shifts in peak position around 1652cm −1 (Fig. 5b i-iii), and we could not observe a statistically significant decrease in second derivative peak height at 1637 cm −1 (P < 0.05, but P > 0.008) in the OligoG CF-5/20 treated samples (Fig. 5c iii) . It is probable that the small sample size used in the current study may contribute towards this lack of significance. Previous molecular modelling observations have shown that OligoG is able to alter the structure of mucus and modulate mucin assembly [25] . We hypothesized this to be as a result of hydrogen bonding between OligoG CF-5/20 and the peptide backbone causing a conformational change in the β-sheet secondary structure of the peptide backbone. The closeness to significance shown in the current study is promising and a larger study may demonstrate significance. We also hypothesize that steric hindrance may have contributed to the lack of significant change noted between OligoG CF-5/ 20 incubated sputum and control sputum spectra at the random coil associated wavenumber, 1652 cm −1 .
Clinical data analysis
The use of portable FTIR has recently been shown to predict acute episodes of chronic obstructive pulmonary disease (COPD) [18] and to the facilitate detection of lung cancer [31, [48] [49] [50] . A potential role for FTIR in CF is not unreasonable given the changes seen in CF mucus with DNA, F-actin, mucin structure, and rheology, which have been associated with pulmonary exacerbations [51] .
All patients (except one) who provided induced sputum samples were taking antibiotics (Table 1) . No correlation was found between the wavenumber changes reported here and antibiotic use, sex, age, use of rhDNase I or forced expiratory volume in 1 s (FEV 1 ).
FTIR analysis, however, does have limitations: It cannot determine the exact molecular structure of compounds, and some vibrations detected by FTIR are attributable to multiple chemical groups. These limitations are being overcome by the development of an FTIR reference library for monosaccharides [18] . Moreover, the IR spectral pattern of untreated CF sputum within the fingerprint region in the current study were shown to be highly similar to that seen in sputum from COPD patients [18] . As sialylation and sulphation of the Lewis x antigen is associated with respiratory disease, FTIR could be further developed to monitor the treatment of CF patients, and identify potential mucosal changes prior to pulmonary exacerbations [18] . However, there is considerable heterogeneity in CF sputum samples, so experiments should be performed with sufficient replication to identify potential outliers [19] . Despite this inherent heterogeneity, FTIR analysis in the current study showed remarkable intra-sample reproducibility, and confirmed key specific binding sites for OligoG CF-5/20 with mucin glycan moieties and the peptide backbone.
Conclusion
These findings demonstrate the use of FTIR analysis to study the interaction of alginate OligoG CF-5/20 with glycan moieties and the peptide backbone of mucin molecules in CF sputum. As increases in sulphation within CF mucins are associated with infection and reduced pulmonary function, this finding suggests a potential mechanism whereby OligoG CF-5/20 modifies the viscoelastic properties of CF sputum.
It is known that patients with cystic fibrosis have sub-optimal adherence to long-term inhaled therapies, but this can be improved through the use of electronic monitoring [52] . The current study shows how a simple FTIR-based protocol can be utilized to detect interaction between OligoG CF-5/20 and sputum mucins. It is feasible that FTIR analysis could be employed to monitor patient adherence to therapy through detection of OligoG CF-5/20 in expectorated sputum, and allow healthcare providers to give additional support to patients who show poor compliance with essential treatments.
